A Delaware federal court entered a $245.2 million final judgment against liquid-biopsy specialist Guardant Health (GH) on August 21, affirming that products covering roughly 90% of the company’s infringement-period revenue willfully violated TwinStrand Biosciences’ DNA sequencing patents.
For long-horizon investors, the ruling matters less as a one-time charge than as a structural cost: Guardant must now pay a 6% royalty on U.S. sales of 11 products – including its flagship Guardant360 CDx, Guardant Reveal and the Shield colorectal-cancer screening test – until the underlying patents expire in March 2033, a seven-year earnings headwind that did not previously appear in consensus models.1
Key Takeaways
- Court upheld willful infringement; Guardant’s appeal bid rejected outright.
- 6% royalty applies to ~90% of Guardant’s infringing-period revenue base.
- Ongoing royalty obligation runs to March 2033, not a clean one-time hit.
Market Context & Revenue Exposure
Guardant operates in the liquid-biopsy segment alongside players such as Exact Sciences and Illumina-backed spin-offs, all of which have faced intensifying patent scrutiny as next-generation sequencing IP matures. The $245.2 million award breaks down into $83.4 million in original damages (from the November 2023 jury verdict), $19.5 million in supplemental damages, $119.4 million in accrued royalties and $22.9 million in pre- and post-judgment interest.1
The sheer breadth of affected products – spanning companion diagnostics, minimal residual disease monitoring and population-level cancer screening – means the royalty drag is not confined to a single pipeline asset but cuts across Guardant’s entire commercial portfolio.
Detailed Analysis: Why the Royalty Structure Is the Bigger Story
The court’s refusal to overturn or retry the November 2023 jury verdict removes the most likely near-term escape route for Guardant. It also explicitly upheld the validity of TwinStrand’s patent claims, closing off an invalidity defence that often underpins post-verdict litigation strategy.1
TwinStrand’s Duplex Sequencing technology, developed at the University of Washington, is engineered to detect rare genetic mutations with greater accuracy than conventional DNA sequencing – precisely the error-correction capability that underpins high-sensitivity liquid biopsy. Because the infringing products collectively represented approximately 90% of Guardant’s revenue during the relevant period, any material volume growth in those lines will arithmetically compound the royalty burden rather than dilute it.
The 6% rate applies specifically to U.S. sales, so international revenue – a growing component for cancer-diagnostics companies seeking to diversify beyond the highly contested domestic market – is not directly encumbered. Investors modelling Guardant’s path to profitability will need to segregate domestic and international product contributions more carefully than before.
Outlook & Management Position
TwinStrand said the final judgment “upholds the validity of the patent claims at issue” and confirmed that royalty payments will continue on the covered products until patent expiry in 2033.1 Guardant had sought to overturn the verdict or secure a new trial; the court rejected both efforts.
“The products and services covered by the ruling accounted for about 90% of Guardant’s revenue during the infringement period,” TwinStrand said in its Monday statement, underscoring the commercial significance of the decision for both parties.
Guardant had not issued a public response at the time of publication. The company retains the option to appeal to the Federal Circuit, though the court’s explicit validation of the patent claims narrows the appellate surface area considerably.
Conclusion
The Delaware judgment transforms what began as a 2023 jury award into a durable cost line embedded in Guardant’s income statement for the better part of a decade. Long-horizon investors should weigh not only the $245.2 million balance-sheet impact but the compounding effect of a 6% royalty on a revenue base the company is actively trying to grow – a dynamic that could materially delay any timeline to sustainable operating profitability.
Not investment advice. For informational purposes only.
References
1Reuters (August 24, 2026). “U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute”. Reuters. Retrieved August 24, 2026.